Are prescription drugs like new cars? Is pharma’s grand bargain a sham? And who keeps your DNA safe?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Nicholas Florko joins us for a discussion of the Trump administration’s efforts to get drug prices into TV ads — and the industry’s vehement opposition. And then we talk about why the best-selling drug in the universe is facing competition overseas but retains a monopoly here in the U.S. Kate Black, 23andMe’s chief privacy officer, talks to us about genetic data security in the age of Facebook leaks and cold-case surprises. Finally, we run through a big-money cancer deal, what to expect from Europe’s big oncology meeting, and the legacy of the late Microsoft co-founder Paul Allen.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Authors
